Inclusion Criteria:  INCL1: have a slow-healing or non-healing ulcer consisting of, but not limited to:  diabetic ulcers (Wagner-Meggitt classification system/ University of Texas classification system: grades 1-3) venous ulcers pressure ulcers (international NPUAP/EPUAP classification system: categories/stages II-IV) burn wounds (second and third degree) skin grafts and flaps infected post-surgical ulcers. Standard wound care has not resulted in sufficient healing after at least two weeks (including first line care) and therefore advanced wound care treatments are necessary as an adjunct therapy to standard wound care.  Note: There is no upper limit for the duration that the wound exists. In case a subject has multiple wounds that meet the in- and exclusion criteria, the wound with the longest duration will be chosen for the study.  INCL2: have a wound with a wound surface area that matches the size of the plasma area of the pad, i.e. a maximum diameter of 3 cm.  INCL3: have a wound with a minimum wound size of 1 cm2.  INCL4: are willing and physically able to carry out all study procedures.  INCL5: have a minimum age of 18 years old.  Exclusion Criteria:  EXCL1: the wound is very exudative, i.e. wounds in which moisture is visible again within a few minutes after patting dry.  EXCL2: any implanted active electronic device, such as a pacemaker, is present.  EXCL3: an electronic medical device is attached to the body, including electronic life support equipment and insulin pumps. If the sole purpose of the medical device is monitoring, the subject is not excluded but it should be noted that use of PLASOMA together with such devices has not been tested and may lead to erroneous operation of the attached device during PLASOMA treatment.  Note: no exclusion if electronic medical device will be detached during PLASOMA treatment.  EXCL4: a metal implant (including stents) in the treatment area, i.e. the area between pad and electrode.  EXCL5: a conductive connection from outside to inside the body at or near the heart is present, e.g. a catheter with electrolyte fluid.  EXCL6: the to-be-treated wound is located on the torso above the navel.  EXCL7: the subject is hospitalized at the time of inclusion or likely to be hospitalized in the near future (14 weeks).  EXCL8: the subject has had (vascular) surgery related to the to-be-treated wound within the previous 2 months.  EXCL9: the subject has any known malignant wound degeneration.  EXCL10: the subject receives treatment with immunosuppressive agents or oral corticosteroids; no exclusion if subject has received a stable dose for at least 2 months and the oral corticosteroid dose does not exceed 7.5 mg/day prednisone or equivalent.  EXCL11: the subject is receiving or likely to receive advanced wound therapies - such as negative pressure therapy, hyperbaric oxygen therapy, biologicals (e.g. skin substitutes, growth factors), electrophysical therapy - until FU1 for the to be-treated wound. Advanced wound dressings are not excluded.  EXCL12: the subject suffers from comorbidity or there are other circumstances (e.g. long lasting COVID-19 symptoms), which in the investigator's opinion, are likely to compromise the outcome of the study or the feasibility of the subject fulfilling the study.  EXCL13: the subject had a COVID-19 infection (i.e. tested positive for COVID-19 or very likely infected with COVID-19 but not confirmed by a COVID-19 test) in the past 6 months (counted from disease onset) and still has persistent symptoms (such as fatigue).  EXCL14: the subject has epilepsy.  EXCL15: the subject is pregnant.  EXCL16: the subject is unable to provide consent.  EXCL17: the subject participates in another clinical study.